In silico docking reveals possible Riluzole binding sites on Nav1.6 sodium channel: Implications for amyotrophic lateral sclerosis therapy

Journal of Theoretical Biology

Volumn 315, Issue , 2012, Pages 53-63

  Sierra Bello, Omar ^a   Gonzalez, Janneth ^a   Capani, Francisco ^b   Barreto, George E ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b Inst de Invest Cardiologicas   (Argentina)

Author keywords

ALS; GLN 1799; Nav1.6; Riluzole

Indexed keywords

GLUTAMINE; LEUCINE; RILUZOLE; SODIUM CHANNEL NAV1.6; TYROSINE;

AMINO ACID; DISEASE TREATMENT; DRUG; EXPERIMENTAL DESIGN; NEUROLOGY; SODIUM; TOXICITY;

AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG DESIGN; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN INTERACTION;

AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; BINDING SITES; CELL MEMBRANE; COMPUTATIONAL BIOLOGY; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; NAV1.6 VOLTAGE-GATED SODIUM CHANNEL; PROTEIN STRUCTURE, SECONDARY; PROTEIN SUBUNITS; REPRODUCIBILITY OF RESULTS; RILUZOLE; SEQUENCE ALIGNMENT; SOFTWARE; SOLVENTS; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 84868223335     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2012.09.004     Document Type: Article

References (80)

1. ACD/ChemSketch, Advanced Chemistry Development, Toronto, ON, Canada, 2012.
2. Ackerman M., Clapham D. Ion channels-basic science and clinical disease. Massachusetts Medical Society 1997, 336:157-224.
3. Aggarwal S., Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008, 5:516-527.
4. + channels, Kv1.5 and Kv3.1, by riluzole. Neuroscience 2005, 133:1007-1019.
5. Ajroud-Driss S., Saeed M., Khan H., Siddique N., Hung W.Y., Sufit R., Heller S., Armstrong J., Casey P., Siddique T., Lukas T.J. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS. Amyotroph Lateral Scler. 2007, 8:305-309.
6. Altschul S., Madden T., Schäffer A., Zhang J., Zhang Z., Miller W., Lipman D. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25:3389-3402.
7. Alvaro G., Estevez A., Jean-Marie S., Luis B. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur. J. Pharmacol. 1995, 280:47-53.
8. Andrews J. Amyotrophic lateral sclerosis: clinical management and research update. Curr. Neurol. Neurosci. Rep. 2009, 9:59-68.
9. Araki T., Kumagai T., Tanaka K., Matsubara M., Kato H., Itoyama Y., Imai Y. Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res. 2001, 918:176-181.
10. Azbill M.XPlease provide the full name of autors.., Springer R.D. J.E. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Mol. Brain Res. 2000, 871(2):175-180.
11. Bahram M., Klaus K., Hafis M., Reinhard D., Johannes B. Interaction of The Neuroprotective Drug Riluzole with GABAA and Glycine Receptor Channels. Eur. J. Pharmacol. 2001, 415:135-140.
12. Bairoch A., Apweiler R. The Swiss-Prot protein sequence database: its relevance to human molecular medical research. Mol. Med. 1997, 75:312-316.
13. Balamurugan R., Stalin A., Ignacimuthu S. Molecular docking of g-sitosterol with some targets related to diabetes. Eur. J. Med. Chem. 2011, 47:38-43.
14. Benkert P., Biasini M., Schwede T. Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics 2011, 27:343-350.
15. Berman H., Westbrook J., Gilliland F.Z.G., Bhat T., Weissig H., Shindyalov I., Bourne P. The Protein Data Bank. Nucleic Acids Res. 2000, 28:235-242.
16. Cagdas T., Miook C., Yousin S. Discovery of functional gene variants associated with human longevity: opportunities and challenge. J. Gerontol. 2011, 67A. 376-383.
17. Catterall W., Goldin A., Waxman S. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacologica 2005, 57:397-409.
18. Cheah B., Vucic S., Krishnan A., Kiernan M. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 2010, 17:1942-1959.
19. Chou K. Using amphiphilic pseudo amino acid composition to predict enzyme subfamily classes. Bioinformatics 2004, 21:10-19.
20. Clark J., Pritchard C., Sunak S., 2005. Amyotrophic lateral sclerosis, a report on the state of research into the cause, cure, and prevention of ALS, the ALS Therapy Development Foundation, State of Massachusetts.
21. Clustalw Larkin, ClustalX Bioinformatics 2007, 23:2947-2948.
22. Cornell W., Cieplak P., Bayly C., Gould I., Merz K., Ferguson D., Spellmeyer D., Fox T., Caldwell J., Kollman P. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117:5179-5197.
23. Cornell W., Abseher R., Nilges M., Case D.A. Continuum solvent molecular dynamics study of flexibility in interleukin-8. Novartis Pharmaceutical Corporation, USA 2001, 19:136-145.
24. Damm K.L., Carlson H.A. Gaussian-weighted RMSD superposition of proteins: a structural comparison for flexible proteins and predicted protein structures. Biophys. J. 2006, 90:4558-4573.
25. Denac H., Mevissen M., Scholtysik G. Structure, function and pharmacology of voltage-gated sodium channels. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362:453-479.
26. Desiato M., Palmieri T., Giacobini M., Scalise P., Arcipede A., Caramia F. The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation. J. Neurol. Sci. 1999, 16:98-107.
27. Diss J., Archer S., Hirano J., Fraser S., Djamgoz M. Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate 2001, 48:165-178.
28. Donovan B., Bakshia T., Galbraithb S., Nixona C., Paynec L., Martensa S. Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and Nav1.5 blockade. J. Pharmacol. Toxicol. Methods 2011, 64:269-276.
29. Duclohier H. Structure-function studies on the voltage-gated sodium channel. Biochim. Biophys. Acta 2009, 1788:2374-2379.
30. Dunlop B.M.H., She J., Howland Y. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J. Neurosci. 2003, 23:1688-1696.
31. Foran E., Trotti D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 2009, 11:1587-1602.
32. Fu W., Cui M., Briggs J., Huang X., Xiong B., Zhang Y., Luo X., Shen J., Ji R., Jiang H., Chen K. Brownian dynamics simulations of the recognition of the scorpion toxin maurotoxin with the voltage-gated potassium ion channels. Biophys. J. 2002, 83:2370-2385.
33. Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch A. Protein Identification and Analysis Tools on the ExPASy Server 2005, 571-607. The Proteomics Protocols Handbook. H. Press (Ed.).
34. Gatti M., Tokatly I., Rubio A. Sodium: a charge-transfer insulator at high pressures. Phys. Rev. Lett. 2010, 104:216-404.
35. Gerber N., Lowman H., Artis D.R., Eigenbrot C. Receptor-binding conformation of the ELR motif of IL-8: X-ray structure of the L5C/H33C variant at 2.35 resolution. Proteins 2000, 38:361-367.
36. Hartshorn M., Verdonk M., Chessari G., Brewerton S., Mooij W., Mortenson P., Murray C. Diverse, high-quality test set for the validation of protein-ligand docking performance. J. Med. Chem. 2007, 50:726-741.
37. Hebert T., Drapeau P., Pradier L., Dunn R. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol. Pharmacol. 1994, 1055-1060.
38. Hoffman J.J. Toward a better understanding of amyotrophic lateral sclerosis. Home Healthcare Nurse 2008, 26:337-342.
39. Jorgensen W. Solvation and conformation of methanol in water. Chem. Phys. 1982, 77:4156.
40. Jorgensen W., Tirado-Rives J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J. Am. Chem. Soc. 1988, 110:1657-1666.
41. Karp G. Cell and molecular biology: concepts and experiments 2009, John Wiley & Sons Inc.
42. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., Pon A., Banco K., Mak C., Neveu V., Djoumbou Y., Eisner R., AC G., Wishart D. DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Res. 2010, 39:D1035-D1041.
43. Lambert L.N., De Bolle C., Depiereux X., ESyPred3D E. Prediction of proteins 3D structures. Bioinformatics 2002, 18:1250-1256.
44. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
45. Laurie A., Jackson R. Q-site finder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 2005, 21:1908-1916.
46. Liu S., Zhang C., Zhou H., Zhou Y. A physical reference state unifies the structure-derived potential of mean force for protein folding and binding. Proteins 2004, 56:93-101.
47. MacroModel, Schrödinger, LLC, New York, 2011.
48. *, SuperPose: a simple server for sophisticated structural superposition. Nucleic Acids Res. 2004, 32:W590-W594.
49. Mantegazza M., Curia G., Biagini G., Ragsdale D., Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010, 9:413-424.
50. McGuire D., Garrison L., Armon C., Barohn R.J., Bryan W.W., Miller R., Parry G.J., Petajan J.H., Ross M.A. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group. J. Neurol. Sci. 1997, 152:18-22.
51. Mehta R., Hawthorne M., Peng X., Shilkaitis A., Mehta R., Beattie C., Das Gupta T. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesion. AACR J. 2012, 3:1351-1360.
52. Melnik B.C. Leucine signaling in the pathogenesis of type 2 diabetes and obesity. World J. Diabetes 2012, 3:38-53.
53. Miller R., Mitchell D., Lyon M., Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, 3.
54. Morris A., MacArthur M., Hutchinson E., Thornton J. Stereochemical quality of protein structure coordinates. Proteins 1992, 12:345-364.
55. Nikolaev Y., Pervushin K. Structural basis of RNA binding by leucine zipper GCN4. Protein Sci. 2012, 21:667-676.
56. Norris F.H., Denys E.H., Sang K., Mukai E. The natural history of ALS in a specified population, with comments on risk factors, prognosis and symptomatic treatments. Rinsho Shinkeigaku 1989, 29:1485-1492.
57. O'Boyle M., Banck M., James C., Morley C., Vandermeersch T., Hutchison G. Open Babel: an open chemical toolbox. J. Cheminf. 2011, 33:1186-1758.
58. Pettersen E., Goddard D., Huang C., Couch S., Greenblatt M., Meng C., Ferrin.E. Comput. Chem. 2004, 13:1605-1612.
59. + channels. Pharmacology 1996, 93:9270-9275.
60. + channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesions. Neuroscience 2006, 137:211-220.
61. Saeed U., Nawaz N., Waheed Y., Chaudry N., Tariq Bhatti H., Urooj S., Waheed H. In silico identification of BIM-1 (2-methyl-1H-indol-3-yl) as a potential therapeutic agent against elevated protein kinase C beta associated diseases. Afr. J. Biotech. 2012, 11:4434-4441.
62. Savelieff M., Wilson T., Elias Y., Nilges M., Garner D., Lu Y. Experimental evidence for a link among cupredoxins: red, blue, and purple copper transformations in nitrous oxide reductase. Proc. Nat. Acad. Sci. U.S.A. 2008, 105:7919-7924.
63. Schrödinger, L., 2011. The PyMOL Molecular Graphics System.
64. Schwartz G., Fehlings M.G. Secondary injury mechanisms of spinal cord trauma: a noveltherapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog. Brain Res. 2002, 137:177-190.
65. Shashank D. Voltage-gated sodium channel modulation of calcium dynamics and NMDA receptor signaling in murine neocortical neuron, Faculty of Phylosophy, The University of Georgia. Athens Giogia 2003, 170.
66. Shen H., Chou K. Ensemble classifier for protein fold pattern recognition. Bioinformatics 2006, 22:1717-1722.
67. Song J., Sheng Huang C., Nagata G., Yeh J.Z., Narahashi T. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J. Pharmacol. Exp. Ther. 1997, 282:707-714.
68. Srinivasan J., Trevathan M.W., Beroza P., Case D.A. Application of a pairwise generalized Born model to proteins and nucleic acids: Inclusion of salt effects. Theor. Chem. Acc. 1999, 101:426-434.
69. Suhre K., Sanejouad Y. ElNe'mo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement. Nucleic Acids Res. 2004, 32:W610-W614.
70. Syed R., Rani R., Sabeena A., Ahmad Masoodi T., Shafi G., Alharbi K. Functional analysis and structure determination of alkaline protease from Aspergillus flavus. Bioinformation 2012, 8:175-180.
71. Tarnawa I., Bölcskei H., Kocsi P. Blockers of voltage-gated sodium channels for the treatment of central nervous system disease. Recent Pat. CNS Drug Discovery 2007, 2:57-78.
72. Tavakoli M. Disease progression in amyotrophic lateral sclerosis identifying the cost-utility of riluzole by disease stage. Eur. J. Health Econ. 2002, 3:156-165.
73. Thompson J., Higgins D., Gibson T. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22:4673-4680.
74. Tsui V., Case D.A. Molecular dynamics simulations of nucleic acids using a generalized Born solvation model. J. Am. Chem Soc. 2000, 122:2489-2498.
75. Tytgat J., Peigneur S. The sophisticated peptide chemistry of venomous animals as a source of novel insecticides acting on voltage-gated sodium channels, Insecticides-advances in integrated pest management. Intech 2012.
76. Van Den Bosch L., Van Damme P., Bogaert E., Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006, 1762:1068-1082.
77. Wallace A., Laskowski R., Thornton J. Derivation of 3D coordinate templates for searching structural databases: application to Ser-His-Asp catalytic triads in the serine proteinases and lipases. Protein Sci. 1996, 5:1001-1101.
78. + current and activation of BKCa channels in cultured differentiated human skeletal muscle cells. Life Sci. 2008, 82:11-20.
79. Wokke J. Riluzole. Lancet 1996, 348:1660-1661.
80. Yiangou Y., Facer P., Chessell I.P., Bountra C., Chan C., Fertleman C., Smith V., Anand P. Voltage-gated ion channel Nav1.7 innervation in patients with idiopathic rectal hypersensitivity and paroxysmal extreme pain disorder (familial rectal pain). Neurosci. Lett. 2007, 427:77-82.